(Q36164823)

12 August 2017

1 reference

title

IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status (English)

1 reference

12 August 2017

0 references

Isabel Illa

1

1 reference

12 August 2017

publication date

1 May 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

252 Suppl 1

1 reference

12 August 2017

page(s)

I14-8

1 reference

https://scigraph.springernature.com/pub.10.1007/s00415-005-1104-5

12 August 2017

exact match

0 references

cites work

A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-1104-5

Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-1104-5

Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-1104-5

Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-1104-5

A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-1104-5

Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-1104-5

Treatment of autoimmune myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-1104-5

A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-1104-5

Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients

21 January 2018

1 reference

12 December 2020

Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines

1 reference

12 December 2020

Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy

1 reference

12 December 2020

Pathophysiology of myasthenia gravis

1 reference

12 December 2020

Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets

1 reference

12 December 2020

Polymyositis, dermatomyositis and inclusion-body myositis

1 reference

12 December 2020

Polymyositis and dermatomyositis

1 reference

12 December 2020

Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies

1 reference

12 December 2020

Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis

1 reference

12 December 2020

Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin

1 reference

12 December 2020

Intravenous immunoglobulin for myasthenia gravis

1 reference

12 December 2020

Antibodies in myasthenia gravis and related disorders

1 reference

12 December 2020

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

1 reference

12 December 2020

Lambert-Eaton Myasthenic Syndrome

1 reference

12 December 2020

Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis

1 reference

12 December 2020

Immunoglobulin treatment in refractory Myasthenia gravis.

1 reference

12 December 2020

Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome

1 reference

12 December 2020

Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients

1 reference

12 December 2020

Immunoglobulin therapy in inflammatory myopathies

1 reference

12 December 2020

Treatment of myasthenia gravis with high-dose intravenous immunoglobulin

1 reference

12 December 2020

Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety.

1 reference

12 December 2020

Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome

1 reference

12 December 2020

Effect of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome with small-cell lung cancer: correlation with the titer of anti-voltage-gated calcium channel antibody

1 reference

12 December 2020

A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia

1 reference

12 December 2020

Therapeutic approaches in patients with inflammatory myopathies

1 reference

12 December 2020

Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis

1 reference

12 December 2020

High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study

1 reference

12 December 2020

Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis

1 reference

12 December 2020

Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis

1 reference

12 December 2020

3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome

1 reference

12 December 2020

1 reference

12 December 2020

High-dose intravenous gammaglobulin for myasthenia gravis

1 reference

12 December 2020

The molecular pathophysiology in inflammatory myopathies

1 reference

12 December 2020

Lambert-Eaton myasthenic syndrome

1 reference

12 December 2020

Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide

1 reference

12 December 2020

Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis

1 reference

12 December 2020

10.1007/S00415-005-1104-5

Identifiers

DOI

1 reference

12 August 2017

1 reference